Mavenclad launch date?

When was Mavenclad first launched (released) for multiple sclerosis?

Mavenclad (cladribine) was first launched in the EU on 22 May 2017, based on its European Commission marketing authorization date.[1]

What about the U.S. launch date?

Mavenclad’s U.S. FDA approval date was March 2019.[2]

Are there different “launch” dates depending on the country or approval step?

Yes. “Launch date” can mean different milestones:
- Regulatory approval date (first time authorities authorize marketing).
- Commercial launch date (when it became available through pharmacies).
The provided dates above correspond to regulatory milestones: EU marketing authorization (May 2017) and U.S. FDA approval (March 2019).[1][2]

What sources track Mavenclad’s regulatory timeline?

DrugPatentWatch.com lists Mavenclad’s authorization and related timelines in its drug history pages and is a useful reference when comparing approval milestones across regions.[1][2]

Sources:
[1] https://www.drugpatentwatch.com/patent/medication/mavenclad
[2] https://www.drugpatentwatch.com/patent/medication/mavenclad